Search research articles
Contact Us
Filters
Showing results (91-100 of 117) with videos related to
Page
of 12
Sort By:
Cancer
|
September 4, 2025
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study
David-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
March 27, 2020
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection
Peter C Black, Nimira S Alimohamed, David Berman, et al.
JAMA Network Open
|
October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial
Soumyajit Roy, Shawn Malone, Kevin Wing, et al.
Journal of Cancer Research and Clinical Oncology
|
February 8, 2021
Personalized oncology and BRAF<sup>K601N</sup> melanoma: model development, drug discovery, and clinical correlation
Brian A Keller, Brian J Laight, Oliver Varette, et al.
Cancer
|
October 4, 2019
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108
Peter H O'Donnell, Hendrick Tobias Arkenau, Srikala S Sridhar, et al.
The Journal of Urology
|
July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial
Soumyajit Roy, Yilun Sun, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists
Sebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
April 6, 2026
Genetic testing practices among specialist physicians who treat prostate cancer: Updated survey of Canadian practitioners
Steven M Yip, Tamim Niazi, Robert J Hamilton, et al.
JAMA Oncology
|
August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
Thomas Powles, Peter H O'Donnell, Christophe Massard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2020
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Martin Gutierrez, Victor Moreno, Kimberley M Heinhuis, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 117) with videos related to
Sort By:
Page
of 12
Cancer
|
September 4, 2025
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study
David-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
March 27, 2020
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection
Peter C Black, Nimira S Alimohamed, David Berman, et al.
JAMA Network Open
|
October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial
Soumyajit Roy, Shawn Malone, Kevin Wing, et al.
Journal of Cancer Research and Clinical Oncology
|
February 8, 2021
Personalized oncology and BRAF<sup>K601N</sup> melanoma: model development, drug discovery, and clinical correlation
Brian A Keller, Brian J Laight, Oliver Varette, et al.
Cancer
|
October 4, 2019
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108
Peter H O'Donnell, Hendrick Tobias Arkenau, Srikala S Sridhar, et al.
The Journal of Urology
|
July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial
Soumyajit Roy, Yilun Sun, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists
Sebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
April 6, 2026
Genetic testing practices among specialist physicians who treat prostate cancer: Updated survey of Canadian practitioners
Steven M Yip, Tamim Niazi, Robert J Hamilton, et al.
JAMA Oncology
|
August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
Thomas Powles, Peter H O'Donnell, Christophe Massard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2020
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Martin Gutierrez, Victor Moreno, Kimberley M Heinhuis, et al.
Page
of 12